medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Number S1

<< Back Next >>

Ann Hepatol 2006; 5 (S1)

Module XlX
Cost efficacy and cost–benefit of treatment of hepatitis C

Sánchez ÁJF

Language: English
References: 36
Page: 69-73
PDF size: 52.44 Kb.


Text Extraction

The combination of the high costs of new drugs and limited resources necessitates economic evaluation of all new therapeutic options. Socioeconomic evaluations seek to optimize the use of available resources by identifying, evaluating, measuring, and comparing various alternatives to interventions, diagnoses, or therapies. Thus, new interventions do not have to cost less if resources are used in a more efficient way. The benefits of interventions are defined in terms of clinical, psychosocial or economic outcomes.


REFERENCES

  1. Conceptos básicos en Evaluación económica. En Drummond MF, O’Brien BJ Sttodart GL, Torrance GW. Métodos para la evaluación económica de los programas de asistencia sanitaria. Segunda Edición. Ediciones Díaz Santos 2001.

  2. Drummond MF, Richardson WS, O’Brien BJ, Levine M, Heyland D. Users’ guides to the medical literature: XIII. How to use an article on economic analysis of clinical practice: A. Are the results of the study valid? JAMA 1997; 277: 1552-7.

  3. O’Brien BJ, Heyland D, Richardson WS, Levine M, Drummond MF. Users’ guides to the medical literature: XIII. How to use an article on economic analysis of clinical practice: B. What are the results and will they help me in caring for my patients? JAMA 1997; 277: 1802-6.

  4. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36: S30-S34.

  5. Kim WR, Brown RS, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002: 36: 227-42.

  6. Murray CJ, López AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-76.

  7. Kim WR. Global epidemiology and burden of hepatitis C. Microbes Infect 2002; 4: 1219-25.

  8. Alter MJ, Kruszon-Moran D, Nainan OV, et al. Prevalence of hepatitis C virus infection in the United States. N Eng J Med 1999; 341: 556-62.

  9. Armstrong GL, Alter MJ, McQuillan GM, Margollis HS. The past incidence of hepatitis C infection: implications for the future burden of chronic liver diseases in the United States. Hepatology 2000; 31: 777-82.

  10. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-8.

  11. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122(5): 1500-11.

  12. Grant WC, Jhaveri RR, McHutchison JG, Schulman KA, Kauf TL. Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology 2005; 42: 1406-13.

  13. Deuffic S, Buffat L, Poynard T, et al. Modeling the hepatitis C virus epidemic in France. Hepatology 1999; 29: 1569-601.

  14. Law MG. Modeling the hepatitis C virus epidemic in Australia. Hepatitis C virus projections working group. J Gastroenterol Hepatol 1999; 14: 1100-07.

  15. Buti M, San Miguel R, Brosa M, Cabases JM, Medina M, Angel Casado M, Fosbrook L, Esteban R. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005; 42: 639-45.

  16. Mendez-Sánchez N, Aguilar-Ramírez JR, Reyes A, Dehesa M, Juárez A, Castaneda B, Sánchez-Avila F, Poo JL, Guevara González L, Lizardi J, Valdovinos MA, Uribe M, Contreras AM, Tirado P, Aguirre J, Rivera-Benítez C, Santiago-Santiago R, Bosques-Padilla F, Muñoz L, Guerrero A, Ramos M, Rodríguez-Hernández H, Jacobo-Karam J; Grupo de Estudio, Asociación Mexicana de Hepatología. Etiology of liver cirrhosis in Mexico. Ann Hepatol 2004; 3(1): 30-3.

  17. Mendez-Sanchez N, Villa AR, Chavez-Tapia NC, Ponciano-Rodriguez G, Almeda-Valdes P, Gonzalez D, Uribe M. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005; 4(1): 52-5.

  18. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339(21): 1485-92.

  19. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 1998; 352(9138): 1426-32.

  20. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK; Hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34(2): 395-403.

  21. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358(9286): 958-65.

  22. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975-82.

  23. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140(5): 346-55.

  24. National Institutes of Health. Consensus Development Conference Statement: Management of hepatitis C. June 2002. http://www.consensus.nih.gov

  25. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30(5): 1318-24.

  26. Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG. Costeffectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol 2000; 95(6): 1524-30.

  27. Buti M, Casado MA, Fosbrook L, Esteban R. Cost effectiveness of the treatment of chronic hepatitis C with interferon-alpha. Gastroenterol Hepatol 1998; 21(4): 161-8.

  28. Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R. Costeffectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol 2000; 33(4): 651-8.

  29. Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17(5): 687-94.

  30. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB; German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52(3): 425-32.

  31. Wong JB, Nevens F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta Gastroenterol Belg 2002; 65(2): 110-11.

  32. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290(2): 228-37.

  33. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004; 8(39): iii-iv,1-125.

  34. Siebert U, Sroczynski G; German Hepatitis C Model GEHMO Group; HTA Expert Panel. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care 2005; 21(1): 55-65.

  35. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38(3): 645-52.

  36. Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK. International Hepatitis Interventional Therapy Group. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003; 98(11): 2354-62.




2020     |     www.medigraphic.com